Related Experiment Videos
Secondary leukemia with a translocation (8;21)?
S V Davies1, J A Murray, S M Bowser-Riley
1Department of Hematology, Selly Oak Hospital, Birmingham, Great Britain.
Cancer Genetics and Cytogenetics
|April 1, 1988
Summary
Acute myeloid leukemia (AML) can develop years after cancer treatment. This case shows AML with features of both new and therapy-linked disease, highlighting diagnostic challenges.
Area of Science:
- Hematology
- Oncology
- Cancer Genetics
Background:
- Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy.
- Secondary leukemias can arise following cytotoxic therapy for other cancers.
- Distinguishing therapy-linked AML from de novo AML is clinically significant.
Observation:
- A patient developed AML 10 years post-treatment for osteosarcoma with radiotherapy and chemotherapy.
- The patient presented with FAB M2 morphology and the characteristic t(8;21) translocation, typical of de novo AML.
- Additional cytogenetic abnormalities and chemotherapy resistance suggested a therapy-linked secondary leukemia.
Findings:
- The patient's AML exhibited a mix of de novo and secondary leukemia characteristics.
- The presence of t(8;21) is common in de novo AML, while additional aberrations and resistance point to therapy-induced changes.
- This case underscores the complexity in classifying AML in patients with a history of cancer treatment.
Implications:
- Accurate classification of AML is crucial for appropriate treatment strategies.
- Therapy-linked AML may require different management approaches compared to de novo AML.
- Further research is needed to refine diagnostic criteria for therapy-linked leukemias.